IVDseminar2Dec04Clas sifying5

Information about IVDseminar2Dec04Clas sifying5

Published on October 21, 2007

Author: Connor

Source: authorstream.com

Content

Classifying your IVD:  Classifying your IVD Robyn Wood Medical Devices Assessment Section Office of Devices Blood and Tissues Risk Associated with IVDs:  Risk Associated with IVDs Risks of IVD to patients and users can range from little or no risks to patients and users significant potential risk Hence the level of regulation should be proportional to the level of potential risk, taking account of the benefits offered by the device Risk based classification system based on GHTF guidelines How Potential Risk is Determined:  How Potential Risk is Determined the intended use and indications as specified by the manufacturer Specific disorder, condition or risk factor for which the test is intended The technical/ scientific/ medical expertise of the intended user eg lab testing vs home use How Potential Risk is Determined:  How Potential Risk is Determined The importance of the information to the diagnosis Sole determinant or one of several The impact of the result (true or false) to the individual and/or to public health How Potential Risk is Determined:  How Potential Risk is Determined These guidelines are encompassed in a set of classification rules Rules classify all IVD into 4 different classes The rules are capable of accommodating future technological developments These mirror GHTF rules Why Classify?:  Why Classify? The purpose of classification rules is to determine the level of regulatory oversight required The class of device determines the conformity assessment procedure Slide7:  Class I no public health risk / low personal risk Class 2 low public health risk / moderate personal risk Class 3 high personal risk / moderate public health risk Class 4 high public health risk Class 1:  Class 1 Devices in this class represent no public health risk, or low personal risk Lab equipment intended for use in IVD testing Eg HPLC, automated differential cell counter Culture media Class 2:  Class 2 Devices in this class represent a low public health risk, and moderate personal risk Includes those IVD that detect the presence or exposure to infectious agents not easily propagated in Aust and NZ Cause self-limiting disease Not used exclusively in a diagnostic setting An erroneous result rarely puts the individual in immediate danger Class 2:  Class 2 Devices in this class represent a low public health risk, and moderate personal risk Includes sodium, ALT, lactic dehydrogenase, ferritin or folate, computerised cervical cytology, tests for Epstein Barr virus, autoimmune tests, and genetic tests for thrombophilia mutation screening, Anti-DNA Abs, Anti-ENA Abs, Anti-GAD Abs, Anti-IAZ Abs, Abs for diagnosing Coeliac disease, Cardiolipin antibodies, anti-TSH receptor, AMA. Class 3:  Class 3 Devices in this class represent a moderate public health risk, and high individual risk Includes those IVD that detect the presence or exposure to infectious agents that are easily propagated in Aust and NZ An erroneous result may have a major negative impact on outcome Where the IVD provides the critical or sole determinant for a correct diagnosis Class 3:  Class 3 moderate public health risk, high individual risk Includes IVDs used for tests for diseases on the NZ Notifiable Diseases schedules and the Aust Notifiable Diseases list, eg SARS Blood and tissue screening in selected populations. Examples: tests for CMV, malaria, West Nile Virus, Parvovirus B19. Class 3:  Class 3 moderate public health risk, high individual risk Includes Detecting the presence of, or exposure to, a serious sexually transmitted agent. Such as Chlamydia trachomatis, Neisseria gonorrhoeae etc. Detecting the presence in cerebrospinal fluid or blood of an infectious agent that constitutes a significant public health risk. Examples: Neisseria meningitidis or Cryptococcus neoformans. Determining infective disease status or immune status, and where there is a risk that an erroneous result will lead to a patient management decision resulting in an imminent life-threatening situation for the patient. Example: Influenza, Haemophilus influenzae B Class 3:  Class 3 moderate public health risk, high individual risk Includes Detecting the presence of an infectious agent where there is a significant risk that an erroneous result would cause death or severe disability to the individual or foetus being tested. Examples: Toxoplasma, Varicella Zoster Virus. Screening pre-natal women in order to determine their immune status towards transmissible agents. Examples: Rubella. Class 3:  Class 3 moderate public health risk, high individual risk Includes Screening for, or in the diagnosis of, cancer, including cancer staging, where initial therapeutic decisions will be made based on the outcome of the test results. Predictive genetic screening, when the outcome of the test would ordinarily result in a substantial impact on the life of the individual. Examples: Guthrie test for phenylketonuria, Huntington’s Disease, Cystic Fibrosis. Class 3:  Class 3 moderate public health risk, high individual risk Includes Monitoring levels of medicines, substances or biological components, when there is a risk that an erroneous result will lead to a patient management decision resulting in an immediate life-threatening situation for the patient. Examples: Cardiac markers, cyclosporine, prothrombin time testing, digoxin, paracetamol, Gentamycin, Tobramycin, potassium, calcium, troponin, glucose, taerolimus, serolimus Class 4:  Class 4 Devices in this class represent a high public health risk, and high individual risk Includes all IVDs used for universal screening of the blood supply and organ and tissue donations for pathogens HIV, HCV, HBV, Syphilis, HTLV Includes IVDs for these agents used in a diagnostic role IVDs for these agents intended only for monitoring are captured under a separate role - are Class III Class 4:  Class 4 high public health risk, high individual risk Includes IVDs with an intended function of detecting agents used in biowarfare eg anthrax Includes high risk blood grouping tests ABO, rhesus, anti-Kell Points to remember:  Points to remember The manufacturer is responsible for applying the classification rules The classification rules are based on the manufacturer’s intended purposes and in some cases, more than 1 rule may apply If this happens the higher classification applies Points to remember:  Points to remember The classification must be consistent with the information accompanying the IVD including the label, directions for use, brochures and operating manuals If the intended purpose is not clear, the Joint Agency will assign an intended purpose consistent with purpose generally accepted in clinical practice Points to remember:  Points to remember Calibrators and control materials intended to be used with an IVD reagent should be treated in the same class as the IVD itself Software intended to drive or influence the use of the IVD falls under the same classification as the IVD Questions?:  Questions?

Related presentations


Other presentations created by Connor

Positive Psychology
19. 11. 2007
0 views

Positive Psychology

bev salt
04. 10. 2007
0 views

bev salt

animal cc
11. 10. 2007
0 views

animal cc

Implants1
12. 10. 2007
0 views

Implants1

Thermal Hist
16. 10. 2007
0 views

Thermal Hist

mosquitoes
21. 10. 2007
0 views

mosquitoes

Semantic Analysis
29. 09. 2007
0 views

Semantic Analysis

NRCCWDT DataAbuse 71907 post
29. 10. 2007
0 views

NRCCWDT DataAbuse 71907 post

Basic Level Leadership I
02. 11. 2007
0 views

Basic Level Leadership I

Bulgaria Challenge 2006 EN
26. 11. 2007
0 views

Bulgaria Challenge 2006 EN

Cheuvreux 07062006 Kurkilahti
15. 10. 2007
0 views

Cheuvreux 07062006 Kurkilahti

Pendergast Finland Keynote
23. 12. 2007
0 views

Pendergast Finland Keynote

CERN
16. 10. 2007
0 views

CERN

Philips TVA EPG LowCost STB EN
12. 10. 2007
0 views

Philips TVA EPG LowCost STB EN

AfricanCinema
19. 02. 2008
0 views

AfricanCinema

WaltersUofMN
17. 10. 2007
0 views

WaltersUofMN

Experience Curve 02 06 01
24. 02. 2008
0 views

Experience Curve 02 06 01

T227 3 2
14. 02. 2008
0 views

T227 3 2

Lect 20
10. 03. 2008
0 views

Lect 20

gallat
04. 03. 2008
0 views

gallat

Bioavail equiv3S
17. 10. 2007
0 views

Bioavail equiv3S

TrackingAtTheLinearC ollider
18. 03. 2008
0 views

TrackingAtTheLinearC ollider

manow601
24. 03. 2008
0 views

manow601

RB STRATEGIE DENTREPRISE
24. 10. 2007
0 views

RB STRATEGIE DENTREPRISE

PRNL Environmental Leadership
29. 02. 2008
0 views

PRNL Environmental Leadership

caterpillar final
10. 04. 2008
0 views

caterpillar final

2410745
13. 04. 2008
0 views

2410745

b philips
16. 02. 2008
0 views

b philips

CHAP02
14. 04. 2008
0 views

CHAP02

Matt Davey
16. 04. 2008
0 views

Matt Davey

Haas0324
17. 04. 2008
0 views

Haas0324

Rod Oram
17. 10. 2007
0 views

Rod Oram

Land Vital Records
18. 04. 2008
0 views

Land Vital Records

Farr
07. 01. 2008
0 views

Farr

inv22
28. 04. 2008
0 views

inv22

prlaws molleda04
25. 10. 2007
0 views

prlaws molleda04

iCare Product Presentation
07. 05. 2008
0 views

iCare Product Presentation

4 2
11. 10. 2007
0 views

4 2

gallastegui
22. 10. 2007
0 views

gallastegui

37733 1
30. 04. 2008
0 views

37733 1

Auto Categorization
02. 05. 2008
0 views

Auto Categorization

sec self train
02. 05. 2008
0 views

sec self train

chen
09. 10. 2007
0 views

chen

03 12 pitaro
16. 11. 2007
0 views

03 12 pitaro

regionalism
28. 12. 2007
0 views

regionalism

Rana ppt parallel3 4
16. 03. 2008
0 views

Rana ppt parallel3 4

Commuting to Downtown
30. 10. 2007
0 views

Commuting to Downtown

kobes hilltop 01
19. 10. 2007
0 views

kobes hilltop 01

generalppp
22. 10. 2007
0 views

generalppp

industry info march02
17. 10. 2007
0 views

industry info march02

68 jvc
05. 10. 2007
0 views

68 jvc

lrec06 assist pres
07. 03. 2008
0 views

lrec06 assist pres

Cross Compiler Issues
05. 10. 2007
0 views

Cross Compiler Issues

file10836
20. 11. 2007
0 views

file10836

EnergyFilmFestival
18. 10. 2007
0 views

EnergyFilmFestival

Fun Slide Show
02. 11. 2007
0 views

Fun Slide Show

IBM Nov 26 final1
16. 10. 2007
0 views

IBM Nov 26 final1

rahn esp
25. 10. 2007
0 views

rahn esp

Lesson16 Italy
23. 10. 2007
0 views

Lesson16 Italy

P6 Janes
19. 10. 2007
0 views

P6 Janes

russia pres
12. 10. 2007
0 views

russia pres

Dow
27. 09. 2007
0 views

Dow

Creswell hsgneed101206
31. 10. 2007
0 views

Creswell hsgneed101206

EolssDemo
15. 10. 2007
0 views

EolssDemo

State of the Temple
04. 12. 2007
0 views

State of the Temple

IndEdRoundtableed JVas1
07. 01. 2008
0 views

IndEdRoundtableed JVas1

SuperMACHO
15. 11. 2007
0 views

SuperMACHO